<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104372">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02138461</url>
  </required_header>
  <id_info>
    <org_study_id>JH-ALG-MDB-1301</org_study_id>
    <nct_id>NCT02138461</nct_id>
  </id_info>
  <brief_title>Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops</brief_title>
  <official_title>Subjective Patient Assessment Comparing Overall Tolerability and Satisfaction of a Prostaglandin Analogue Including Either Bimatoprost 0.01% or Latanoprost.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MDbackline, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MDbackline, LLC</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines patient perceptions regarding the tolerability of two classes of
      glaucoma medication:  bimatoprost and latanoprost.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients enrolled in this study completed a validated survey instrument (COMTOL) examining
      tolerability of topically applied ophthalmic medications that they are already taking in
      their regular course of care for glaucoma.  The purpose of the study is to determine whether
      side effects and symptoms of the drugs already being taken cause problems with activities of
      daily living.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Tolerability of medications as measured by the COMTOL validated instrument</measure>
    <time_frame>at the time of enrollment in the clinic, patients will immediately complete the questionnaire and exit the study</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients who are already taking the medications of interest will be enrolled from a general ophthalmology practice.  Immediately after consenting to participate, they will complete a validated survey instrument called the Comparison of Ophthalmic Medication for Primary Outcome Measure Tolerability (COMTOL) questionnaire (Ophthalmology 1997; : 104:334-342). Because this study will not be a crossover trial design, and patients will only continue taking the medications they were prescribed in the course of their glaucoma therapy, the modified version will eliminate questions in the COMTOL related to subjective comparison of two medications and instead focus on tolerability of the single medication being taken by test subjects.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>bimatoprost</arm_group_label>
    <description>These patients take bimatoprost topically for glaucoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>latanoprost group</arm_group_label>
    <description>These patients take latanoprost topically for glaucoma.</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Note patients will be recruited to fill out a questionnaire, describing their symptoms
      related to glaucoma use drops.  In this study, we are examining only patients taking either
      bimatoprost or latanoprost, thus 2 cohorts. However, this is not an interventional study,
      and there will be only one study visit (enrollment and questionnaire at the same time) and
      no change in the patient's prescribed therapy.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients taking either study medication for glaucoma.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with glaucoma taking either bimatoprost or latanoprost

        Exclusion Criteria:

          -  patients taking other medication or with other causes for ocular surface symptoms
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A. Hovanesian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Jules Stein Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Savak Teymoorian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Eye Associates</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol Hardy, BS</last_name>
    <phone>949 900 5248</phone>
    <email>chardy@harvardeye.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harvard Eye Associates</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Hardy</last_name>
      <phone>949-951-2020</phone>
    </contact>
    <investigator>
      <last_name>Savak Teymoorian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John A Hovanesian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>May 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>bimatoprost</keyword>
  <keyword>latanoprost</keyword>
  <keyword>tolerability</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
